De Maria Maurizio, Mogorovich Andrea, Giannarini Gianluca, Manassero Francesca, Selli Cesare
Division of Urology, Department of Surgery, University of Pisa, Pisa, Italy.
J Endourol. 2006 Jul;20(7):525-9. doi: 10.1089/end.2006.20.525.
As many as 96% of patients report some kind of discomfort/pain during transrectal ultrasonography (TRUS)-guided prostate biopsy, and when pain is severe, it may be necessary to decrease the planned number of biopsies or interrupt the procedure. Various modalities have been recommended to alleviate the pain, but reports on efficacy are contradictory. We assessed the possible benefit of intrarectal and perianal lidocaine-prilocaine (EMLA) cream.
A series of 98 patients without active anal and prostatic conditions underwent TRUS and, 10 to 31 days later, TRUS-guided biopsy. They were asked to grade their discomfort/pain using a 10- point linear visual analog pain scale (VAS). After TRUS, patients were divided into three groups on the basis of the VAS scores. Group 1 (N = 8) had pain scores <or=2 (mild pain/discomfort). Group 2 (N = 75) had pain scores between 2 and 5 (moderate pain/discomfort). Group 3 (N = 15) had pain scores >or=5 (severe pain/discomfort). Each group was then randomized to receive local anesthesia with intrarectal and anal EMLA cream (subgroup A) or intrarectal and anal ultrasound gel as placebo (subgroup B). Pain scoring was repeated after the biopsy.
In group 1, there were no significant differences in pain scores between subgroups A and B. In group 2, we could not complete the biopsy in one patient of subgroup B. A statistically significant difference was noticed between the VAS scores of subgroup A and subgroup B (P < 0.0001). In group 3, we were not able to complete biopsy in 5 patients of subgroup B. We noticed significantly higher VAS scores in subgroup B between TRUS and prostate biopsy (P < 0.0001), whereas similar scores were observed in subgroup A (P = NS). A statistically significant difference (P < 0.0001) was noticed between subgroup A and subgroup B scores during biopsy.
In patients with high tolerance for simple TRUS, needle trauma does not significantly alter tolerability, and anesthetic provides little benefit for prostatic biopsy. However, the opposite is true in patients presenting moderate to significant pain/discomfort at TRUS, who may benefit from intrarectal/anal administration of EMLA during prostate biopsy.
多达96%的患者在经直肠超声(TRUS)引导下前列腺穿刺活检过程中会报告某种不适/疼痛,当疼痛严重时,可能有必要减少计划的穿刺活检数量或中断操作。已推荐多种方法来减轻疼痛,但关于疗效的报告相互矛盾。我们评估了直肠内及肛周利多卡因-丙胺卡因(EMLA)乳膏的潜在益处。
98例无活动性肛门及前列腺疾病的患者接受了TRUS检查,并在10至31天后接受了TRUS引导下的活检。要求他们使用10分线性视觉模拟疼痛量表(VAS)对不适/疼痛进行评分。TRUS检查后,根据VAS评分将患者分为三组。第1组(N = 8)疼痛评分≤2(轻度疼痛/不适)。第2组(N = 75)疼痛评分在2至5之间(中度疼痛/不适)。第3组(N = 15)疼痛评分≥5(重度疼痛/不适)。然后将每组随机分为接受直肠内及肛门EMLA乳膏局部麻醉的亚组A或接受直肠内及肛门超声凝胶作为安慰剂的亚组B。活检后重复疼痛评分。
在第1组中,亚组A和亚组B的疼痛评分无显著差异。在第2组中,亚组B的1例患者未能完成活检。亚组A和亚组B的VAS评分存在统计学显著差异(P < 0.0001)。在第3组中,亚组B的5例患者未能完成活检。我们注意到亚组B在TRUS检查和前列腺活检之间的VAS评分显著更高(P < 0.0001),而亚组A观察到类似评分(P =无显著性差异)。活检期间亚组A和亚组B的评分存在统计学显著差异(P < 0.0001)。
对于对单纯TRUS耐受性高的患者,穿刺针创伤不会显著改变耐受性,麻醉剂对前列腺活检益处不大。然而,对于在TRUS检查时出现中度至重度疼痛/不适的患者则相反,他们可能在前列腺活检期间从直肠内/肛门给予EMLA中获益。